Inventiva S.A (IVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inventiva S.A (IVA) has a cash flow conversion efficiency ratio of 1.796x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-51.24 Million ≈ $-59.90 Million USD) by net assets (€-28.52 Million ≈ $-33.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Inventiva S.A defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Inventiva S.A - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Inventiva S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inventiva S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inventiva S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GCI Liberty, Inc.
NASDAQ:GLIBK
|
0.045x |
|
Dalian Sunasia Tourism Holding Co Ltd
SHG:600593
|
0.428x |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
-0.026x |
|
Shandong Mining Machinery Group Co Ltd
SHE:002526
|
0.049x |
|
AB SKF (publ)
ST:SKF-A
|
-0.008x |
|
Dilip Buildcon Limited
NSE:DBL
|
-0.441x |
|
Kvutzat Acro Ltd.
TA:ACRO
|
-0.030x |
|
Resurs Holding AB
ST:RESURS
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Inventiva S.A (2013–2025)
The table below shows the annual cash flow conversion efficiency of Inventiva S.A from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Inventiva S.A.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-28.52 Million ≈ $-33.35 Million |
€-104.88 Million ≈ $-122.62 Million |
3.677x | +356.39% |
| 2024-12-31 | €-106.65 Million ≈ $-124.68 Million |
€-85.93 Million ≈ $-100.46 Million |
0.806x | -68.38% |
| 2023-12-31 | €-32.03 Million ≈ $-37.45 Million |
€-81.61 Million ≈ $-95.42 Million |
2.548x | +357.90% |
| 2022-12-31 | €45.48 Million ≈ $53.17 Million |
€-44.93 Million ≈ $-52.53 Million |
-0.988x | -84.33% |
| 2021-12-31 | €88.87 Million ≈ $103.89 Million |
€-47.63 Million ≈ $-55.68 Million |
-0.536x | -94.85% |
| 2020-12-31 | €111.21 Million ≈ $130.02 Million |
€-30.59 Million ≈ $-35.76 Million |
-0.275x | +59.92% |
| 2019-12-31 | €41.39 Million ≈ $48.39 Million |
€-28.40 Million ≈ $-33.21 Million |
-0.686x | -23.57% |
| 2018-12-31 | €61.60 Million ≈ $72.01 Million |
€-34.21 Million ≈ $-39.99 Million |
-0.555x | -109.07% |
| 2017-12-31 | €64.01 Million ≈ $74.83 Million |
€-17.00 Million ≈ $-19.88 Million |
-0.266x | +36.15% |
| 2016-12-31 | €35.72 Million ≈ $41.76 Million |
€-14.86 Million ≈ $-17.37 Million |
-0.416x | -27.24% |
| 2015-12-31 | €42.77 Million ≈ $50.00 Million |
€-13.98 Million ≈ $-16.35 Million |
-0.327x | -13.88% |
| 2014-12-31 | €51.51 Million ≈ $60.22 Million |
€-14.79 Million ≈ $-17.29 Million |
-0.287x | -5.83% |
| 2013-12-31 | €59.01 Million ≈ $68.99 Million |
€-16.01 Million ≈ $-18.72 Million |
-0.271x | -- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more